explore -WSS

explore

author：explore 2025-09-02 11:43:16 - browse：846

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Eli Lilly reports tirzepatide MASH success during Q4 earnings

explore

WSS

Tome Biosciences co

FDA approves first treatment for ultra

FDA approves first treatment for ultra

Websites selling Wegovy, Zepbound ingredients targeted by FDA

ActiGraph execs on goal of drug approvals with digital endpoints

Ukraine taking heavy casualties 10 weeks into its counteroffensive

entertainment

explore

hotspot

In Memoriam: Notable people who died in 2023

New definition of a human embryo proposed amid rapid advances

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New definition of a human embryo proposed amid rapid advances

Walensky prepares to leave CDC — and Congress — behind

Baltimore teen accused of firing into crowd during block party mass shooting

Duchenne breakthrough therapy leaves behind pioneering families

The pain doctors face in trying to build their families

Duchenne breakthrough therapy leaves behind pioneering families

Hilary may become 1st tropical storm to make landfall in California in 84 years

knowledge

Congress might make insulin pumps more accessible to the blind

Abbott's new heart device gets FDA advisory panel nod

ProMED sees offers of support, but its future remains unclear

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Trump's false claims about Georgia's 2020 election long debunked

Juul documents reveal insider tactics on political lobbying

explore

hotspot

entertainment

hotspot